Jun 17, 2020
Emgality® Demonstrates Reduction in Frequency, Duration, and Pain Severity in Patients with Episodic and Chronic Migraine
Jun 16, 2020
Lilly's OVERCOME Study Reveals Less than 30 Percent of People Living with Migraine Take Recommended Prescription Medications
Jun 15, 2020
Impel NeuroPharma Presents Data From INP104 Clinical Program In Acute Migraine At The 2020 American Headache Society (AHS) Virtual Annual Scientific Meeting
Jun 08, 2020
Phase 2 Clinical Trial of LSD for "Suicide Headaches" Begins Treating Patients
May 26, 2020
Emgality® Shows Improvement in Work Productivity and Health and Well-Being Between Attacks in Patients with Migraine and a History of Preventive Treatment Failure
Dec 23, 2019
FDA approves new treatment for adults with migraine
Dec 18, 2019
Lilly Announces the Launch of TRIUMPH, the First, Long-Term, Real-World Evidence Study of Emgality® (galcanezumab-gnlm)
Nov 20, 2019
Impel NeuroPharma Announces Publication Of Narrative Review In The Journal Headache Supporting Need For Novel Formulations Of Dihydroergotamine (DHE) In Addressing Acute Treatment Of Migraine
Nov 08, 2019
National Spine and Pain Centers to Honor Veterans with Free Spine Exams
Nov 08, 2019
American Headache Society Publishes Article Demonstrating the Promise of Remote Electrical Neuromodulation (REN) as First-Line Treatment for Acute Migraine Relief
Oct 29, 2019
WAT Medical will be returning to 2019 MEDICA to exhibit their innovative wearable technologies
Oct 24, 2019
ShiraTronics, Inc. Completes $33M Million Series A Financing
Oct 02, 2019
Upsher-Smith Laboratories Launches Tosymra(TM) (sumatriptan) Nasal Spray For The Acute Treatment Of Migraine In Adults
Sep 26, 2019
Currax(TM) Pharmaceuticals LLC Announces First Acquisition: Acquires North American Rights to ONZETRA® Xsail®
Sep 15, 2019
Five US patents granted for non-invasively treating migraine headaches in the most unexpected of ways - gentle air pressure changes in the ear
Sep 05, 2019
Impel NeuroPharma to Present Data From INP104 Clinical Program at the 19th Congress of the International Headache Society
Sep 03, 2019
Impel NeuroPharma Announces Last Patient Enrolled In Phase 3 Trial Evaluating INP104 For The Treatment Of Acute Migraine
Aug 08, 2019
Lilly Announces Positive Results for Emgality(TM) (galcanezumab) from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments
Aug 05, 2019
Lilly Announces Positive Results for Emgality® (galcanezumab-gnlm) from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments
Jul 20, 2019
Upsher-Smith Laboratories Completes Acquisition Of Two Treatments For Acute Migraine In Adults